The life sciences industry is competitive, volatile, and constantly changing—three reasons the Securities and Exchange Commission (SEC) scrutinizes life sciences companies’ pre- and post-IPO filings.
Streamline your company’s filing process by reviewing our annual report, Under the Microscope: An Analysis of SEC Comment Letter Trends Among Middle-Market and Pre-IPO Life Sciences Companies.
The in-depth report takes a look at SEC comment letter trends directed toward S-1, 10-K, 10-Q, and 20-F filings; comparisons to prior years; and implications for your middle market or pre-IPO life sciences company.
Stay current on evolving industry trends and standards—sign up to receive alerts, articles, and event notifications.
Thank you. Your contact request has been received. We will be in touch soon.